echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Xinlitai Class 1 New Drug Application for Clinical Treatment of Major Depression

    Xinlitai Class 1 New Drug Application for Clinical Treatment of Major Depression

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    On December 8, the official website of the State Food and Drug Administration showed that the clinical application of Shenzhen Xinlitai Pharmaceutical's SAL0114 tablets was accepted by the State Food and Drug Administration.

    The indications to be applied are severe depression, etc.

    Depression is a common mental illness with high prevalence, recurrence and disabilit.



    Studies have shown that the prevalence of depression in China has reached 2.1%; the lifetime prevalence of depression in Chinese adults is 6.8%, and the utilization of health services for patients with depression is low and they rarely receive adequate treatmen.



    Most of the antidepressant drugs currently on the market take several weeks to take effect, and there are unmet clinical need.



    With the improvement of living standards and the increase of people's health awareness, it is expected that the market for depression will continue to expan.

    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.